Hydroxyurea does not appreciably reduce JAK2 v617F allele burden in patients with polycythemia vera or essential thrombocythemia

Haematologica

Volumn 95, Issue 8, 2010, Pages 1435-1438

  Antonioli, Elisabetta ^a   Carobbio, Alessandra ^b   Pieri, Lisa ^a   Pancrazzi, Alessandro ^a   Guglielmelli, Paola ^a   Delaini, Federica ^a   Ponziani, Vanessa ^a   Bartalucci, Niccolò ^a   Tozzi, Lorenzo ^a   Bosi, Alberto ^b   Rambaldi, Alessandro ^a   Barbui, Tiziano ^b   Vannucchi, Alessandro M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Essential thrombocythemia; Hydroxyurea; JAK2V617F; Polycythemia vera

Indexed keywords

ACETYLSALICYLIC ACID; CELL DNA; HYDROXYUREA; JANUS KINASE 2;

ADOLESCENT; ADULT; AGED; ALLELE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; HUMAN; LETTER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PHARMACOGENETICS; PHLEBOTOMY; POLYCYTHEMIA VERA; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTHEMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMINO ACID SUBSTITUTION; FEMALE; GENE FREQUENCY; HUMANS; HYDROXYUREA; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; NUCLEIC ACID SYNTHESIS INHIBITORS; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, ESSENTIAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956018987     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.021444     Document Type: Letter

References (10)

1. Theocharides A, Passweg JR, Medinger M, Looser R, Li S, Hao-Shen H, et al. The allele burden of JAK2 mutations remains stableover several years in patients with yeloproliferative disorders. Haematologica. 2008;93(12):1890-3.
2. Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlue J, et al. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol. 2009;37(10):1186-93 e7.
3. Girodon F, Schaeffer C, Cleyrat C, Mounier M, Lafont I, Dos Santos F, et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica. 2008;93(11):1723-7.
4. Ricksten A, Palmqvist L, Johansson P, Andreasson B. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica. 2008;93(8):1260-1.
5. Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B, et al. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica. 2008;94(1):38-45.
6. Bock O, Hoftmann J, Theophile K, Hussein K, Wiese B, Schlue J, et al. Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines. Am J Pathol. 2008;172(4):951-60.
7. Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol. 2009;37(9):1016-21.
8. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113(20):4829-33.
9. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006;107(9):3676-82.
10. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007;110(3):840-6.